Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

characterisation of immunoglobulin subclasses

PreclinicalBiologic

UUniversity Hospital, Rouen

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q1 2027

Pruritus

NCT05689463

Clinical

Trials by Indication[1]

Pruritus1 trial

Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy

Recruiting·UUniversity Hospital, Rouen·N/A·NCT05689463·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for characterisation of immunoglobulin subclasses. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — characterisation of immunoglobulin subclasses compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for characterisation of immunoglobulin subclasses. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Rouen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Rouen

Related News